Thioacetamide-induced hepatocarcinoma in rat

Area of Science:

• Hepatology
• Oncology
• Biochemistry

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern.
• Thioacetamide (TAA) is a chemical agent used to induce liver damage and HCC in animal models.
• Understanding the early cellular and biochemical changes in TAA-induced HCC is crucial for developing effective therapies.

Purpose of the Study:

• To investigate the development of hepatocellular carcinoma in rats fed with thioacetamide.
• To examine the morphological and biochemical alterations in hepatocytes during TAA-induced carcinogenesis.
• To identify novel localizations of key enzymes within hepatocytes and HCC cells.

Main Methods:

• Rats were administered thioacetamide (TAA) for extended periods (up to 495 days).
• Hepatocellular carcinoma incidence and metastasis were assessed.
• Morphological changes in hepatocyte nucleoli were observed.
• Enzyme activities of succinate dehydrogenase and glucose-6-phosphatase were analyzed in cytoplasm and nucleoli.

Main Results:

• Hepatocellular carcinoma developed in 4 out of 56 TAA-fed rats.
• Two of the four tumors exhibited lung metastasis.
• TAA administration led to a significant increase in hepatocyte nucleoli size.
• Succinate dehydrogenase and glucose-6-phosphatase were localized in both cytoplasm and nucleoli, with nucleolar localization being a novel finding.
• Malignant cells in HCC showed a complete loss of glucose-6-phosphatase activity but retained succinate dehydrogenase activity.

Conclusions:

• Thioacetamide reliably induces hepatocellular carcinoma in rats, with potential for metastasis.
• TAA treatment causes significant nucleolar hypertrophy in hepatocytes.
• The study identified novel nucleolar localizations for succinate dehydrogenase and glucose-6-phosphatase.
• Alterations in glucose-6-phosphatase activity in malignant cells may serve as a biomarker for HCC progression.